Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis (ICROS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03620409
Recruitment Status : Recruiting
First Posted : August 8, 2018
Last Update Posted : September 13, 2018
Sponsor:
Collaborators:
Department of Anesthesiology and Intensive Care Medicine, JUH
Department of Cardiothoracic Surgery, JUH
Department of Clinical Chemistry and Laboratory Medicine, JUH
Department of Biochemistry, Center for Molecular Biomedicine (CMB), FSU Jena
Systems Biology and Bioinformatics, Hans-Knöll Institute Jena
Institute of Pharmacy, FSU Jena
Information provided by (Responsible Party):
Sina Coldewey, Jena University Hospital

Brief Summary:

Sepsis is a life-threatening condition which can affect people of any age. An infection triggers a host response resulting in organ failure. The extent of the organ dysfunction varies between patients and during the course of the condition. Thus far, the only causal treatment option consists in treating the infection early e. g. by an operation or the use of antibiotics. Owing to advances in modern critical care, more patients survive sepsis. Nonetheless, sepsis survivors frequently show impaired organ function, physical disability and considerably decreased health-related quality of life.

It is hypothesized that sepsis-induced cardiac dysfunction - septic cardiomyopathy - may influence mortality. The relationship between occurrence of cardiovascular dysfunction and metabolic changes in the course of sepsis remains unclear. Therefore, the aim of this study is the investigation of cardiovascular function, oxygen consumption and metabolic changes in septic patients. Apart from cardiological routine procedures (echo- and electrocardiography) a newly developed method for measuring the oxygen tension and consumption and bioelectrical impedance analysis for body composition estimation will be employed. Through blood and urine analysis, both routine parameters and parameters focusing on patient metabolism will be analysed.

Septic patients will be assessed in the acute phase (3 and 7 days after sepsis diagnosis), the stable phase (at intensive care unit discharge) and after full or incomplete recovery (during two outpatient visits at 6 and 12 months after sepsis diagnosis). The results will be compared with healthy individuals and patients with existing heart disease (cardiomyopathy).

The study aims to identify clinical parameters and signaling pathways involved in the development and course of sepsis. Furthermore, specific parameters associated with the medium- and long-term health status, physical performance and quality of life after sepsis are to be identified. The overall aim of the study is the development of novel diagnostic and therapeutic approaches in sepsis.


Condition or disease
Sepsis Septic Cardiomyopathy Cardiomyopathies

Detailed Description:

The overall aim of the study is the identification of theragnostic targets for the development of novel diagnostic and therapeutic approaches in sepsis. In sepsis, a dysregulated host response to infection leads to organ failure. The extent of organ dysfunction varies between patients and at different stages of the disease. Advances in modern critical care have reduced 28-day mortality over the last years. Nonetheless, a large proportion of sepsis survivors reports long-term physical, mental and cognitive impairments (post intensive care syndrome) including persistent organ dysfunction (persistent critical illness). In addition, mortality rates are considerably increased up to years after sepsis. However, the underlying molecular mechanisms remain unclear.

There is evidence that the development of septic cardiomyopathy may influence mortality. The relationship between the occurrence of cardiovascular dysfunction and metabolic changes in the course of sepsis has not yet been investigated. Therefore, the key aim of this study is the investigation of cardiovascular function, oxygen consumption and metabolic changes in septic patients. Apart from cardiological routine procedures (echo- and electrocardiography) a newly developed method for measuring the mitochondrial oxygen tension and consumption (COMET) will be applied. As oedema is involved in the pathogenesis of altered microcirculation in sepsis, endothelial dysfunction will be analysed via a set of surrogate parameters and body composition (especially extracellular water) measurement via bioelectrical impedance analysis. In blood, stool and urine, routine parameters and the metabolome, lipidome and microbiome will be analysed. Septic patients will be assessed in the acute phase (3 and 7 days after sepsis diagnosis), the stable phase (at intensive care unit discharge) and after full or incomplete recovery (during two outpatient visits at 6 and 12 months sepsis diagnosis). Analyses will be complemented by in-depth anamnestic and clinical-epidemiological assessment as well as subsequent information on health related quality of life (EQ-5D-3L) and physical performance (6-minute walk test).

The primary endpoint of the study is the difference in mortality rates between septic patients with and without septic cardiomyopathy six months after sepsis diagnosis. Further research questions include differences in clinical and laboratory parameters between these patient groups during the acute phase, and during the mid-, and long-term course.

The results will be compared with healthy individuals and patients with cardiomyopathy in absence of infection.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 290 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis
Actual Study Start Date : May 9, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Sepsis
Patients with and without diagnosis septic cardiomyopathy
Cardiomyopathy without infection
Patients without operation and patients with scheduled LVAD-Implantation
Healthy subjects
Healthy controls



Primary Outcome Measures :
  1. Mortality differences between septic patients with vs. without septic cardiomyopathy six months after sepsis diagnosis [ Time Frame: Six months after sepsis diagnosis ]
    Difference in mortality rates between septic patients with vs. without septic cardiomyopathy six months after sepsis diagnosis


Secondary Outcome Measures :
  1. Mortality differences between septic patients with vs. without septic cardiomyopathy twelve months after sepsis diagnosis [ Time Frame: Twelve months after sepsis diagnosis ]
    Difference in mortality rates between septic patients with vs. without septic cardiomyopathy twelve months after sepsis diagnosis

  2. Incidence of septic cardiomyopathy [ Time Frame: from enrollment until 3 days after ICU discharge ]
    Estimation of incidence of septic cardiomyopathy in the acute phase of sepsis


Biospecimen Retention:   Samples With DNA
Blood, urine and stool samples.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
primary care and community sample
Criteria

Inclusion Criteria:

Patients with Sepsis:

  • sepsis or septic shock according to Sepsis-3 criteria
  • first infection-associated organ dysfunction (= sepsis diagnosis) no older than 72 hours (first blood sample within 96 hours after sepsis diagnosis)
  • written informed consent of the patient or his legal representative

Patients with cardiomyopathy without inflammation:

  • cardiomyopathy without inflammation
  • written informed consent

Healthy subjects:

- written informed consent

Exclusion Criteria:

Patients with sepsis:

  • cardiac surgery ≤ 12 months
  • sepsis/septic shock ≤ 8 months
  • significant pre-existing heart condition

    • endocarditis
    • higher-grade valvular heart disease (grade 3 valve disease, symptomatic aortic stenosis, medium-degree mitral valve insufficiency with reduced ejection fraction or clinical symptoms)
    • complex structural congenital heart disorders (e.g. TGA, Fallot-Tetralogie, endocardial cushion defect)
    • pre-existing significantly reduced cardiac performance (ejection fraction < 45 % or 10 % below norm value)
    • pre-existing pulmonary hypertension
    • myocardial infarction ≤ 1 year in patient history
    • heart transplantation in patient history
    • permanent atrial fibrillation
  • pneumectomy in medical history
  • contraindication for transesophageal echocardiography (e.g. esophageal resection, higher-grade esophagus varices) and insufficient sonography conditions for transthoracic echocardiography
  • liver cirrhosis Child C
  • terminal kidney disease with dialysis
  • pregnancy/breastfeeding
  • previous participation in this study
  • participation in another intervention study
  • therapy limitation, DNR / DNI order
  • life expectancy ≤ 6 months due to comorbidities
  • cardiopulmonary resuscitation < 4 weeks

Patients with cardiomyopathy without infection:

  • sepsis/septic shock ≤ 8 months
  • acute organ failure (except cardiac decompensation/cardiogenic shock due to dilated cardiomyopathy) ≤ 6 months
  • complex structural congenital heart disorders (e.g. TGA, Fallot-Tetralogie, endocardial cushion defect)
  • infection at point of inclusion
  • cardiogenic shock at point of inclusion
  • heart transplantation in medical history
  • mechanical heart assist device
  • pneumonectomy in medical history
  • liver cirrhosis Child C
  • terminal kidney disease with dialysis
  • contraindication for transesophageal echocardiography (e.g. esophageal resection, higher-grade esophagus varices) and insufficient sonographic conditions for transthoracic echocardiography
  • pregnancy/breastfeeding
  • therapy limitation / DNR / DNI order
  • life expectancy ≤ 6 months due to comorbidities
  • previous participation in this study
  • participation in another interventional study
  • cardiopulmonary resuscitation < 4 weeks

Healthy subjects:

  • sepsis/septic shock ≤ 8 months
  • ICU treatment ≤ 6 months
  • infection at point of inclusion
  • heart surgery (including heart transplantation) in medical history
  • significant pre-existing cardiac condition

    • higher-degree valvular heart disease (grade 3 valve disease, symptomatic aortic stenosis, medium-degree mitral valve insufficiency with reduced ejection fraction or clinical symptoms)
    • complex structural congenital heart disorders (e.g. TGA, Fallot-Tetralogie, endocardial cushion defect)
    • pre-existing significantly reduced cardiac performance (ejection fraction < 45 % or 10 % below norm value)
    • pre-existing pulmonary hypertension
    • myocardial infarction ≤ 1 year in medical history
  • pneumonectomy in medical history
  • liver cirrhosis Child C
  • terminal kidney disease with dialysis
  • contraindication for transesophageal echocardiography (e.g. esophageal resection, higher-grade esophagus varices) and insufficient sonography conditions for transthoracic echocardiography
  • pregnancy/breastfeeding
  • life expectancy ≤ 6 months due to comorbidities
  • previous participation in this study
  • participation in another intervention study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03620409


Contacts
Layout table for location contacts
Contact: Sina M Coldewey, MD, PhD +4936419323101 Sina.Coldewey@med.uni-jena.de
Contact: Charles Neu, MD +4936419323101 charles.neu@med.uni-jena.de

Locations
Layout table for location information
Germany
NWG Translational Septomics, Zentrum für Innovationskomepetenz (ZIK) Septomics, Universitätklinikum Jena Recruiting
Jena, Thuringia, Germany, D-07747
Contact: Sina M Coldewey, MD, PhD    +4936419323101    sina.coldewey@med.uni-jena.de   
Contact: Charles Neu, MD    4936419323101    charles.neu@med.uni-jena.de   
Sponsors and Collaborators
Jena University Hospital
Department of Anesthesiology and Intensive Care Medicine, JUH
Department of Cardiothoracic Surgery, JUH
Department of Clinical Chemistry and Laboratory Medicine, JUH
Department of Biochemistry, Center for Molecular Biomedicine (CMB), FSU Jena
Systems Biology and Bioinformatics, Hans-Knöll Institute Jena
Institute of Pharmacy, FSU Jena
Investigators
Layout table for investigator information
Principal Investigator: Sina M Coldewey, MD, PhD Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital

Additional Information:
Layout table for additonal information
Responsible Party: Sina Coldewey, Principal Investigator, Jena University Hospital
ClinicalTrials.gov Identifier: NCT03620409     History of Changes
Other Study ID Numbers: ZKSJ106-V1.3
DRKS00013347 ( Registry Identifier: DRKS )
First Posted: August 8, 2018    Key Record Dates
Last Update Posted: September 13, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Toxemia
Cardiomyopathies
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Heart Diseases
Cardiovascular Diseases